Robert W. Baird analyst Brian Skorney maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) on Friday, setting a price target of $252, which is approximately 14.97% above the present share price of $219.18.
Skorney expects Vertex Pharmaceuticals to post earnings per share (EPS) of $2.32 for the second quarter of 2021.
The current consensus among 11 TipRanks analysts is for a Moderate Buy rating of shares in Vertex Pharmaceuticals, with an average price target of $278.6.
The analysts price targets range from a high of $347 to a low of $250.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $1.63 billion and a net profit of $746.29 million. The company's market cap is $56.73 billion.
According to TipRanks.com, Robert W. Baird analyst Brian Skorney is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 5.2% and a 50.31% success rate.
Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.